Progress of bortezomib in children with relapsed/refractory B-cell acute lymphoblastic leukemia
10.3760/cma.j.issn.1673-4408.2024.01.006
- VernacularTitle:硼替佐米治疗儿童复发/难治性B系急性淋巴细胞白血病研究进展
- Author:
Yujiao WANG
1
;
Ruibo ZHAO
;
Liangchun HAO
Author Information
1. 中国医科大学附属盛京医院小儿血液科，沈阳 110004
- Keywords:
Children;
Acute lymphoblastic leukemia;
Bortezomib
- From:
International Journal of Pediatrics
2024;51(1):29-33
- CountryChina
- Language:Chinese
-
Abstract:
Acute lymphoblastic leukemia（ALL）is the most common pediatric cancer and has good outcome.However，the prognosis of relapsed/refractory ALL in children is poor.Intensive reinduction chemotherapy and hematopoietic stem cell transplantation have become alternative treatments. Bortezomib，as the primary generation proteasome inhibitor，has been approved for the treatment of multiple myeloma and mantle cell lymphoma. In recent years，several clinical studies have confirmed promising responses and well tolerated of bortezomib combined with various chemotherapeutic drugs in treating children with relapsed/refractory ALL，to improve the complete remission rate and survival rate. This article reviews the mechanisms of bortezomib in ALL and the clinical study progress and safety of bortezomib combined with chemotherapy in children with relapsed/refractory ALL.
